Futuximab Biosimilar - Research Grade

Human

EGFR

>1mg/ml

IgG1 - kappa

CHO Cells

Bulk Anti-Human EGFR (EGFR.1) Antibody (ICH1021), Cetuximab Biosimilar - Research Grade (ICH4004), Matuzumab Biosimilar - Research Grade (ICH4007), Nimotuzumab Biosimilar - Research Grade (ICH4008), Panitumumab Biosimilar - Research Grade (ICH4028), Zalutumumab Biosimilar - Research Grade (ICH5116), Necitumumab Biosimilar - Research Grade (ICH5121), Depatuxizumab Biosimilar - Research Grade (ICH5294), Becotatug Biosimilar - Research Grade (ICH5378), Demupitamab Biosimilar - Research Grade (ICH5473), Imgatuzumab Biosimilar - Research Grade (ICH5600), Laprituximab Biosimilar - Research Grade (ICH5626), Losatuxizumab Biosimilar - Research Grade (ICH5657), Modotuximab Biosimilar - Research Grade (ICH5691), Pimurutamab Biosimilar - Research Grade (ICH5774), Serclutamab Biosimilar - Research Grade (ICH5853), Tomuzotuximab Biosimilar - Research Grade (ICH5933)

https://www.imgt.org/mAb-DB/

ICH3002

P00533

Blue ice

This product is an unconjugated, non-therapeutic recombinant analog of the anti-EGFR antibody futuximab, produced as a research-grade reagent (human IgG1, kappa) for laboratory use only. It reproduces the antigen-binding specificity of the originator molecule directed against the human epidermal growth factor receptor, making it a convenient tool for studying EGFR engagement without the constraints of clinical material. Typical research applications include use as a defined positive control or benchmarking reagent in EGFR binding assays (ELISA, flow cytometry, SPR/BLI affinity work), as a capture or detection component in immunoassays, in ligand-blocking and receptor-neutralisation experiments, and as a scaffold for ADCC characterisation or antibody-drug-conjugate development workflows. It is supplied at research-grade purity with low endotoxin (typically <1 EU/mg, with ultra-low <0.5 EU/mg options), and is available in bulk milligram-to-gram quantities to support in-vitro assays, reagent standardisation, and preclinical model work. It is strictly for research use only and is not the clinical drug; it is not intended for human or veterinary use. EGFR (epidermal growth factor receptor; ERBB1/HER1, UniProt P00533) is a single-pass transmembrane receptor tyrosine kinase of the ERBB family. Ligands such as EGF and TGF-alpha bind the extracellular domain, driving receptor homo- or heterodimerisation (including with HER2/HER3), trans-autophosphorylation of the cytoplasmic kinase domain, and activation of downstream RAS-RAF-MAPK, PI3K-AKT, and STAT signalling that promote proliferation, survival, and migration. EGFR is frequently dysregulated in epithelial cancers through overexpression, activating kinase-domain mutations, or gene amplification, and is a validated oncology target. Anti-EGFR antibodies typically bind domain III of the ectodomain, blocking ligand binding and dimerisation and promoting receptor internalisation, which underlies both their signalling-inhibitory and immune-effector (ADCC) mechanisms.

Proto-oncogene c-ErbB-1, Receptor tyrosine-protein kinase erbB-1, Epidermal growth factor receptor, ERBB, ERBB1, HER1

This monoclonal antibody was purified using Protein A

Sterile, preservative-free, solution in PBS. BSA and Azide free.

This biosimilar is stable when stored at 2-8°C. For longer term storage (> 3 months) it is recommended to store this antibody at -20°C or -70°C.

Functional Assays

This biosimilar is for research use only (RUO): it is not for diagnostic or therapeutic procedures and cannot be purchased by patients.

Products are for research use only. Not for use in diagnostic or therapeutic procedures.

3-4 weeks